NPR Analysis Finds TrumpRx Lists Discounts on Under 12% of Participating Drugmakers' Brand-Name Medicines

A Website Promised a Supermarket, Delivered a Boutique

On July 16, 2026, NPR published an analysis of TrumpRx.gov, the federal website the Trump administration launched in February to offer cash-paying patients discounts on brand-name prescription drugs^[3][12]. Comparing the site's listings against the Food and Drug Administration's database of drugs on the market, NPR found that TrumpRx carries discounts on roughly 92 brand-name medicines — fewer than 12% of the more than 800 brand-name drugs sold by the 17 pharmaceutical companies that signed pricing deals with the administration^[1][2]. As of mid-July, 15 of those 17 companies had at least one drug listed; two, Gilead and Regeneron, had none, though both told NPR they would each add a single drug^[1]. The White House did not respond to NPR's questions about how many patients have used the site or which drugs sell most^[1].

The site traces back to an executive order Trump signed in May 2025 seeking "most-favored-nation" pricing, an effort to align U.S. drug prices with the lower prices paid by other wealthy nations, and the resulting manufacturer deals were negotiated against a backdrop of administration threats to impose tariffs on pharmaceutical imports^[1][2]. A banner on the TrumpRx site claiming more than $400 million in savings for Americans had not been updated in over a month at the time of NPR's report, and NPR said it could not independently verify the figure^[1].

What Isn't in Dispute

Both supporters and critics of the program agree on the basic contours of what TrumpRx is and does. It is a real website, launched February 5, 2026, offering direct-to-consumer cash discounts on select brand-name drugs^[3][12]. The administration says it has reached deals with 16 to 17 manufacturers that it describes as representing about 86% of the U.S. branded-drug market^[14]. Pfizer, the company with the most drugs listed, says it offers savings of up to 85% off list prices on more than 30 medicines — though some of its biggest sellers, including Eliquis, Ibrance and Paxlovid, are not discounted on the site^[1]. And independent of how the numbers are framed, the underlying gap NPR identified — 92 listed discounts against a pool of more than 800 eligible drugs — is not contested by any side in the debate^[1][2].

The Incentives Pulling Each Side

The dispute is less about the raw numbers than about which numbers matter. The administration has a political incentive to publicize a tangible win on drug prices, a concern that polls well across party lines, which rewards emphasizing the count of manufacturer deals and headline discount percentages rather than the share of each company's full catalog that is actually discounted^[4]. Drugmakers, for their part, face pressure to appear cooperative with the administration and avoid the threatened tariffs, while protecting revenue on their highest-grossing drugs — an arrangement that can rationally produce a narrow menu of discounted, lower-revenue products rather than a companywide price cut^[1]. Democratic lawmakers and health-policy researchers, meanwhile, have an incentive to document any gaps between promise and delivery and to use them to argue for structural measures such as direct Medicare price negotiation^[9].

How the Administration and Its Critics Each See It

The White House frames TrumpRx as a historic achievement built on real leverage: deals with manufacturers it says cover about 86% of the branded-drug market, an expanding list of discounted drugs, and steep advertised cuts on high-demand medicines like Wegovy and Ozempic, which officials say fall from roughly $1,000 or more a month to as low as $149 to $350 through the site^[13][14]. Officials argue this is a first-of-its-kind use of tariff leverage and most-favored-nation pricing to bring Americans closer to the prices paid in other wealthy countries, and the administration is pushing to codify the pricing framework in a broader "Great Healthcare Plan" now before Congress^[4][15]. It is worth noting, as NPR's analysis does, that these headline figures largely describe deals reached and manufacturers' overall market share rather than the number of drugs actually discounted on the site^[1][4].

Democratic senators and independent researchers see a thinner reality underneath those figures. They point to a Senate Democratic report finding that some signatory companies raised list prices on hundreds of other drugs even after signing on to TrumpRx, and that new drugs launched during this period at an average annual price of about $353,000^[9]. Ben Rome, a researcher at Brigham and Women's Hospital, told NPR that companies are offering discounts "for a small number of products and in a limited setting"^[1]. Critics also note that for most insured patients, using insurance coverage typically remains cheaper than paying a discounted cash price, and that some TrumpRx-listed prices exceed those of generic equivalents or of the same drug sold in the United Kingdom^[1][7][11]. Their strongest evidence is the documented coverage gap and the price increases identified in the Senate report, though the sharpest versions of this critique — such as characterizations of the program as offering meaningful savings on "exactly one" drug — represent the most extreme reading of the underlying data^[8]. Patients themselves fall somewhere between these frames: those who are uninsured or need drugs rarely covered by insurance, such as fertility or weight-loss medications, can see real and substantial savings, while most insured patients are likely to find their existing coverage cheaper than the TrumpRx cash price^[1].

How the Coverage Split by Ideology

News outlets across the political spectrum covered the same underlying facts through markedly different lenses. Conservative outlets including Fox News and The Washington Times emphasized the program's growth to more than 800 total listed drug options and framed steep percentage discounts on individual medicines as a delivered promise, generally without addressing what share of each manufacturer's full catalog was actually discounted^[5][6]. Left-leaning and health-policy outlets, including KFF Health News, Common Dreams and NBC News' coverage of the Senate Democratic report, instead highlighted the narrowest findings — that list prices rose for many drugs after the deals, that some listed discounts still exceed generic or foreign prices, and that one progressive analysis found only a single drug genuinely offered at a new lower price^[7][8][9].

Coverage from outside the U.S. added a third lens. Al Jazeera and a Reuters analysis carried by U.S. News framed TrumpRx as a domestic pricing experiment built on the threat of tariffs, with the Reuters analysis noting that roughly a third of listed drugs were still cheaper in the UK's state health system — implicitly questioning claims that TrumpRx delivers the lowest available prices^[10][11]. NPR's own reporting, and the FDA database comparison at the center of its analysis, occupied something closer to the empirical middle, anchoring the debate in the measurable distance between the number of drugs the administration's deals made eligible for discounts and the number actually discounted on the site^[1][2].